Form 4: Incyte EVP Vijay Iyengar Reports Significant Equity Grants and Routine Sales

Incyte Corporation's EVP, Vijay K Iyengar, reported a series of equity transactions including the acquisition of restricted stock units, performance shares, and stock options, alongside routine sales and tax-related dispositions.

Summary

• Vijay K Iyengar, EVP, GMAPPS at Incyte Corp (INCY), reported multiple transactions under a Rule 10b5-1 plan.
• On July 14, 2025, 595 shares of common stock were disposed of at $69.98 to satisfy tax withholding obligations.
• On July 15, 2025, 1,177 shares of common stock were sold at $69.86.
• Also on July 15, 2025, 836 shares of common stock were disposed of at $68.25 for tax withholding.
• On July 15, 2025, 6,430 restricted stock units (RSUs) were awarded at a price of $0, which will vest 25% annually over four years and settle one-for-one for common stock.
• Beneficial ownership of common stock following these transactions is 41,523 shares, including 37,752 unvested shares from previous RSU and performance share awards.
• On July 15, 2025, 16,077 performance shares were awarded at $0, which can yield up to 200% of one common share based on Incyte's relative total shareholder return (TSR) over a three-year period starting January 1, 2025, vesting on July 15, 2028.
• On July 15, 2025, 14,472 employee stock options were granted with an exercise price of $68.25, vesting in 37 installments (25% after one year, then monthly over three years) and expiring on July 14, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as the executive received substantial new equity awards (RSUs, performance shares, and stock options), which significantly increase their potential ownership and align their interests with long-term company performance. The dispositions were routine sales and tax withholdings, often part of pre-planned trading strategies.

Positives

• Award of 6,430 restricted stock units (RSUs) at $0, aligning executive interests with long-term shareholder value.
• Grant of 16,077 performance shares, which can potentially double based on strong relative total shareholder return, incentivizing superior company performance.
• Issuance of 14,472 employee stock options with an exercise price of $68.25, providing upside potential tied to stock price appreciation.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating pre-planned and not reactive trading.

Negatives

• Disposition of 1,177 shares of common stock through a sale at $69.86.
• Disposition of 595 shares at $69.98 and 836 shares at $68.25 to cover tax withholding obligations, which are routine but reduce direct share count.

Future Outlook

The future outlook for Vijay K Iyengar's equity holdings includes the vesting of 6,430 restricted stock units over four years, the potential earning and vesting of up to 16,077 performance shares by July 15, 2028, contingent on Incyte's relative total shareholder return, and the vesting of 14,472 employee stock options over approximately four years, expiring in 2035.

Management Comments

• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing reflects routine executive compensation practices within the pharmaceutical and biotechnology industry, where a significant portion of executive pay is often tied to equity awards such as restricted stock units, performance shares, and stock options. These awards are designed to align executive incentives with long-term shareholder value creation and company performance, particularly through metrics like Total Shareholder Return (TSR).

Comparison to Industry Standards

• The structure of equity compensation, including RSUs, performance shares tied to relative TSR, and stock options with multi-year vesting schedules, is consistent with common practices among large-cap pharmaceutical and biotechnology companies.
• While specific comparable companies or projects are not detailed in this filing, this compensation framework is widely adopted by peers like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals to incentivize long-term performance and retention of key executives.

Stakeholder Impact

• Shareholders: The new equity grants align executive incentives with shareholder value creation, particularly through performance shares tied to relative TSR. Routine sales and tax withholdings are expected and generally have minimal impact.
• Employees: The equity compensation structure for a senior executive may reflect broader compensation philosophies within the company, potentially influencing employee morale and retention.

Next Steps

• Continued vesting of 6,430 restricted stock units annually over four years.
• Assessment of Incyte's relative total shareholder return (TSR) over the three-year performance period starting January 1, 2025, to determine the final number of earned performance shares.
• Vesting of 16,077 performance shares on July 15, 2028, subject to continued service and performance conditions.
• Continued vesting of 14,472 employee stock options in 37 installments, with the first 25% vesting after one year and the remainder monthly over three years.

Key Dates

Keywords

Incyte Corp, INCY, SEC Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Performance Shares, Stock Options, Equity Awards, Vijay K Iyengar, Rule 10b5-1